NCT03633461View on ClinicalTrials.gov

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

September 20, 2018

Study Completion Date

September 20, 2018

Conditions
Dry Eye Disease
Interventions
DRUG

OC-02 (simpinicline) nasal spray

OC-02 (simpinicline) nasal spray, 11.1 mg/ml

DRUG

Placebo (vehicle) nasal spray

Placebo (vehicle) nasal spray

Trial Locations (2)

37205

Nashville, Nashville

40206

Louisville, Louisville

Sponsors
All Listed Sponsors
lead

Oyster Point Pharma, Inc.

INDUSTRY

NCT03633461 - Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study) | Biotech Hunter | Biotech Hunter